Acme United Q2 2026 Earnings: EPS and Revenue Beat on MyMedic Acquisition

• Acme United reported Q2 2026 EPS of $1.22, beating estimates by 50.62%, with revenue reaching $62.7 million against a forecast of $58.08 million.
• The strong performance was primarily driven by a 16% year-over-year sales increase, largely attributed to the integration of the MyMedic acquisition.
• Gross margins expanded to 42.6% from 41.0% in the prior year period, indicating improved operational efficiency and cost management.
• Despite the positive results, elevated SG&A expenses at 32% of sales and potential tariff pressures remain key risks for investors.

Acme United Corporation delivered a significant earnings beat for the second quarter of 2026, surpassing analyst expectations on both earnings and revenue metrics. The company reported earnings per share (EPS) of $1.22, which represented a 50.62% surprise compared to the consensus estimate of $0.81. Revenue also exceeded forecasts, posting $62.7 million against a projected $58.08 million, marking a 7.99% positive surprise. This robust financial performance contributed to a substantial stock price surge of approximately 11.92% following the release, pushing the shares near their 52-week high of $51.88. The market reaction underscores investor confidence in the company's ability to navigate current economic headwinds while capitalizing on strategic growth initiatives.

The primary driver of this outperformance was the successful integration of the MyMedic acquisition, which played a pivotal role in boosting top-line growth. The acquisition contributed to a 16% year-over-year increase in sales, demonstrating its immediate impact on the company's revenue streams. Management clarified that even excluding the impact of the acquisition, the company achieved a solid 8% organic growth rate, indicating strong underlying business momentum. This dual engine of acquisition-driven and organic growth provides a diversified foundation for future expansion. The strategic focus on integrating MyMedic also includes plans to expand its distribution channels beyond direct-to-consumer sales into mass retail, which could unlock additional growth opportunities in the coming quarters .

Financial health metrics improved notably during the quarter, with gross margins expanding to 42.6% from 41.0% in the prior year period. This expansion indicates effective cost management and enhanced operational efficiency, allowing the company to maintain pricing power despite a challenging macroeconomic environment . CEO Johnsen emphasized that margin recovery is an ongoing process, citing the strategic replacement of higher-tariff inventory with lower-cost stock as a key factor in alleviating recent cost pressures . The company anticipates continued margin expansion as it navigates tariff-related challenges, with expectations for strong profitability in the fourth quarter driven by seasonal demand . This proactive inventory management strategy highlights the company's agility in responding to external cost fluctuations.

Despite the positive results, investors should remain cautious of key risks that could impact future performance. Selling, General, and Administrative (SG&A) expenses remain elevated at 32% of sales, which could weigh on net profitability if not managed effectively . Additional headwinds include potential increases in tariff and freight costs, currency fluctuations, and uneven geographic performance, with the Canadian market currently lagging behind other regions . These factors introduce uncertainty into the company's forward outlook, particularly as global trade dynamics continue to evolve. The company's current ratio of 3.23 indicates robust short-term solvency, but the elevated SG&A ratio suggests that operational efficiency improvements are still necessary to sustain long-term growth .

Looking ahead, Acme United is scheduled to report its next earnings results on October 27, 2026, covering the period ending in September 2026 . The company's ability to maintain its margin expansion trajectory and successfully integrate MyMedic into its broader distribution network will be critical to sustaining investor confidence. While the stock has shown strong momentum, the combination of elevated SG&A expenses and external tariff pressures requires careful monitoring. The company's value-oriented profile, characterized by strong liquidity and a modest dividend yield of approximately 1.20%, offers a degree of stability for investors seeking exposure to the healthcare and medical device sectors . However, the mixed profitability trends relative to industry peers, with trailing twelve-month EPS declining by 6.32%, highlight the need for continued operational discipline . As the company navigates these complexities, its strategic focus on margin recovery and channel diversification will be key determinants of its long-term success.